Detailed cholesterol testing for Type 2 diabetes patients is the focus of a newly published article by Atherotech Diagnostics Lab Chief Medical Officer Michael E. Cobble, M.D. “Advanced Lipid Testing” appears in the September/October 2010 quarterly issue of Practical Diabetology.
The article discusses the clinical advantages of advanced cholesterol testing in reducing cardiovascular disease (CVD) risk in patients with Type 2 diabetes and details several currently available advanced lipid tests, including the VAP Cholesterol Test from Atherotech. Cobble also explores which patients are appropriate to test and how to apply advanced lipid testing results.
Advanced lipid testing is affordable, widely available and may provide valuable information in the treatment and management of people living with Type 2 diabetes, explained Cobble, who is also a director, researcher and clinician at Canyons Medical Center in Sandy, Utah.
“We know that aggressive management of multiple cardiovascular disease risks in diabetes mellitus patients has proven beneficial,” Cobble said. “But in order to properly treat these patients, we first must identify them and effectively assess their risk. This is achieved through advanced lipid profiles.”
Diabetes is a high-risk CVD condition that affects more than 24 million Americans, and patients with Type 2 diabetes are considered high risk due to traditional CVD risk factors and residual lipid risk factors, all of which can be determined through detailed lipoprotein assays such as the VAP Test.
“Standard lipid tests miss more than half of all at-risk patients, and may actually underestimate the number of lipoprotein particles that can lead to atherosclerotic plaques,” Cobble said. “When it comes to diabetic patients, the standard test simply doesn’t give us enough data to make the best decisions for our patients.”
Advanced lipid tests provide a more sophisticated measurement of LDL, HDL, VLDL, non-HDL and other lipid subcomponents. The Vertical Auto Profile (VAP), for example, reports the relative distribution of cholesterol content of all lipoproteins and subfractions 22 components of blood cholesterol to be exact at no additional cost.
The VAP Test includes Lp(a) and reports all three lipoprotein parameters LDL, non-HDL and apoB considered necessary by the expert consensus guidelines issued by the American Diabetes Association and American College of Cardiology. Unlike the standard lipid profile, the VAP Test directly measures LDL and is therefore unaffected by triglycerides, allowing the test to be performed in non-fasting patients. The VAP Test reports all lipoproteins and apolipoproteins, including apoA1 and the apoB/apoA1 ratio, and it can identify triglyceride remnant markers for Metabolic Syndrome, a precursor and coexistor to diabetes.
The VAP Test is available nationwide and widely covered by insurance. For more information call 877-901-8510 or visit www.atherotech.com. Atherotech Diagnostics Lab is on Twitter, @Atherotech, and also on Facebook at www.Facebook.com/Atherotech.
About Atherotech Diagnostics Lab
Atherotech is a CLIA-certified clinical reference laboratory and cardiodiagnostic company focusing on cardiometabolic tests, including the company’s patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit www.atherotech.com.